» Articles » PMID: 20171517

Radiation Dose-volume Effects in the Spinal Cord

Overview
Specialties Oncology
Radiology
Date 2010 Feb 23
PMID 20171517
Citations 162
Authors
Affiliations
Soon will be listed here.
Abstract

Dose-volume data for myelopathy in humans treated with radiotherapy (RT) to the spine is reviewed, along with pertinent preclinical data. Using conventional fractionation of 1.8-2 Gy/fraction to the full-thickness cord, the estimated risk of myelopathy is <1% and <10% at 54 Gy and 61 Gy, respectively, with a calculated strong dependence on dose/fraction (alpha/beta = 0.87 Gy.) Reirradiation data in animals and humans suggest partial repair of RT-induced subclinical damage becoming evident about 6 months post-RT and increasing over the next 2 years. Reports of myelopathy from stereotactic radiosurgery to spinal lesions appear rare (<1%) when the maximum spinal cord dose is limited to the equivalent of 13 Gy in a single fraction or 20 Gy in three fractions. However, long-term data are insufficient to calculate a dose-volume relationship for myelopathy when the partial cord is treated with a hypofractionated regimen.

Citing Articles

Treatment of non-small cell lung cancer: advances following the introduction of PET-CT and IMRT/VMAT.

Muster J, Alt N, Edelmann M, Anczykowski M, Zwerenz C, Schirmer M Strahlenther Onkol. 2025; .

PMID: 40050448 DOI: 10.1007/s00066-025-02377-0.


Fractionated reirradiation of recurrent high-grade gliomas: Safety with higher reirradiation dose and larger targets.

LeCompte M, Vuppala N, Reyes J, Page B, Croog V, Huang E Neurooncol Adv. 2025; 7(1):vdaf004.

PMID: 39991181 PMC: 11842973. DOI: 10.1093/noajnl/vdaf004.


Safety and Efficacy of Stereotactic Radiosurgery in the Management of Primary Spinal Cord Glioblastoma: A Case Report.

Lazzari G, Montagna A, Benevento I, DAndrea B, Metallo V, Tucciariello R Cancer Manag Res. 2025; 17:349-355.

PMID: 39990275 PMC: 11847440. DOI: 10.2147/CMAR.S509635.


SPECT/CT Dosimetry of Bronchial Artery Tc Macroaggregated Albumin Injection in Pulmonary Malignancies: Feasibility Evaluation of Bronchial Artery Y Radioembolization.

Wehrenberg-Klee E, An T, Heidari P, Huesa-Berral C, Dreher M, Eldridge A Radiology. 2025; 314(2):e240331.

PMID: 39964268 PMC: 11868849. DOI: 10.1148/radiol.240331.


Optimising (re-)irradiation for locally recurrent head and neck cancer: impact of dose-escalation, salvage surgery, PEG tube and biomarkers on oncological outcomes-a single centre analysis.

Schleifenbaum J, Morgenthaler J, Sharma S, Klussmann J, Linde P, Wegen S Radiat Oncol. 2025; 20(1):1.

PMID: 39748422 PMC: 11697932. DOI: 10.1186/s13014-024-02570-y.